Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 15;229(5):1290-1294.
doi: 10.1093/infdis/jiad562.

Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants

Robert A Smith  1   2 , Dana N Raugi  1   2 , Robert S Nixon  1   2 , Moussa Seydi  3 , Nicolas A Margot  4 , Christian Callebaut  4 , Geoffrey S Gottlieb  1   2   5 ; University of Washington–Senegal HIV-2 Study Group
Collaborators, Affiliations

Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants

Robert A Smith et al. J Infect Dis. .

Abstract

The activity of lenacapavir against human immunodeficiency virus type 1 (HIV-1) has been extensively evaluated in vitro, but comparable data for human immunodeficiency virus type 2 (HIV-2) are scarce. We determined the anti-HIV-2 activity of lenacapavir using single-cycle infections of MAGIC-5A cells and multicycle infections of a T-cell line. Lenacapavir exhibited low-nanomolar activity against HIV-2, but was 11- to 14-fold less potent against HIV-2 in comparison to HIV-1. Mutations in HIV-2 that confer resistance to other antiretrovirals did not confer cross-resistance to lenacapavir. Although lenacapavir-containing regimens might be considered for appropriate patients with HIV-2, more frequent viral load and/or CD4 testing may be needed to assess clinical response.

Keywords: HIV-1; HIV-2; SIV; antiretroviral therapy; lenacapavir.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. G. S. G. has received research grants and support from the Bill & Melinda Gates Foundation, Gilead Sciences, Alere Technologies, Merck & Co, Janssen Pharmaceuticals, Cerus Corporation, ViiV Healthcare, Bristol-Myers Squibb, Roche Molecular Systems, Abbott Molecular Diagnostics, and Theratechnologies/TaiMed Biologics, Inc. M. S. has received support from Gilead Sciences. N. A. M. and C. C. are employees of Gilead Sciences. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed

References

    1. Gottlieb GS, Raugi DN, Smith RA. 90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. Lancet HIV 2018; 5:e390–9. - PubMed
    1. Ceccarelli G, Giovanetti M, Sagnelli C, et al. Human immunodeficiency virus type 2: the neglected threat. Pathogens 2021; 10:1377. - PMC - PubMed
    1. Visseaux B, Damond F, Matheron S, Descamps D, Charpentier C. HIV-2 molecular epidemiology. Infect Genet Evol 2016; 46:233–40. - PubMed
    1. De Cock KM, Adjorlolo G, Ekpini E, et al. Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. JAMA 1993; 270:2083–6. - PubMed
    1. Link JO, Rhee MS, Tse WC, et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature 2020; 584:614–8. - PMC - PubMed